

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 August 2008 (07.08.2008)

PCT

(10) International Publication Number
WO 2008/092785 A1

(51) International Patent Classification:

C07D 263/28 (2006.01) A61P 25/00 (2006.01)
C07D 413/04 (2006.01) A61P 3/04 (2006.01)
A61K 31/421 (2006.01) A61P 3/06 (2006.01)
A61K 31/422 (2006.01) A61P 3/10 (2006.01)

(74) Agent: POPPE, Regina; Grenzacherstrasse 124,
CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2008/050765

(22) International Filing Date: 23 January 2008 (23.01.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

07101681.0 2 February 2007 (02.02.2007) EP

(71) Applicant (for all designated States except US): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and


(75) Inventors/Applicants (for US only): GALLEY, Guido [DE/DE]; Katzenbuckelweg 14, 79618 Rheinfelden (DE). GROEBKE ZBINDEN, Katrin [CH/CH]; Laubibergstrasse 61, CH-4410 Liestal (CH). NOR-CROSS, Roger [GB/CH]; Rheinfelderstrasse 2, CH-4305 Olsberg (CH). STALDER, Henri [CH/CH]; Strassburgerallee 83, CH-4055 Basel (CH).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: NOVEL 2-AMINOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS



(57) Abstract: The invention relates to the use of compounds of Formula (I) wherein R¹ is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, or is phenyloxy, benzyl, benzyloxy, -COO-lower alkyl, -O-(CH₂)_n-O-lower alkyl, NH-cycloalkyl, cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for n > 1 may be the same or different; X is a bond, -CHR-, -CHRCHR', -OCH₂-, -CH₂OCHR-, -CH₂

CH₂CH₂-, -SCH₂-, -S(O)₂CH₂-, -CH₂SCH₂-, -CH₂N(R)CH₂-, -cycloalkyl-CH₂- or SiRR'-CH₂-; R/R' may be independently from each other hydrogen, lower alkyl or lower alkyl substituted by halogen; R² is hydrogen, phenyl or lower alkyl; Y is phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl; n is 0, 1, 2 or 3; o is 2 or 3; or to a pharmaceutically suitable acid addition salt for the manufacture of medicaments for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.